Abnormal uptake and release of Ca2+ ions from human malignant hyperthermia-susceptible sarcoplasmic reticulum

Biochemical Pharmacology

Volumn 61, Issue 12, 2001, Pages 1479-1485

  O'Sullivan, Grainne H ^a   McIntosh, James M ^a   Heffron, J J A ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Ca2+ loading ability; Ca2+ induced Ca2+ release; Calsequestrin; Malignant hyperthermia; Sarcoplasmic reticulum

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; HALOTHANE; PYROPHOSPHATE; RUTHENIUM RED; RYANODINE RECEPTOR; TRIFLUOPERAZINE;

ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; LEG MUSCLE; MALE; MALIGNANT HYPERTHERMIA; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; SARCOPLASMIC RETICULUM; TRANSPORT KINETICS;

ANIMALS; BIOLOGICAL TRANSPORT; CALCIUM; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MUSCLE, SKELETAL; RATS; RATS, WISTAR; SARCOPLASMIC RETICULUM;

EID: 0035876977     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00604-9     Document Type: Article

References (32)

1. Harrison G.G. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth. 47:1975;62-65.
2. Denborough M. Malignant hyperthermia. Lancet. 352:1998;1131-1136.
3. 2+ regulation defects . Physiol Rev. 76:1996;537-592.
4. Kalow W., Grant D.M. Pharmacogenetics. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular basis of inherited disease. 7th Edn. 1997;293-326 McGraw-Hill, New York.
5. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperthermia Group. Br J Anaesth. 56:1984;1267-1269.
6. Ørding H., Brancadoro V., Cozzolino S., Ellis F.R., Glauber V., Gonano E.F., Halsall P.J., Hartung E., Heffron J.J., Heytens L., Kozak-Ribbens G., Kress H., Krivosic-Horber R., Lehmann-Horn F., Mortier W., Nivoche Y., Ranklev-Twetman E., Sigurdsson S., Snoeck M., Stieglitz P., Tegazzin V., Urwyler A., Wappler F. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group . Acta Anaesthesiol Scand. 41:1997;955-966.
7. Manning B.M., Quane K.A., Ording H., Urwyler A., Tegazzin V., Lehane M., O'Halloran J., Hartung E., Giblin L.M., Lynch P.J., Vaughan P., Censier K., Bendixen D., Comi G., Heytens L., Monsieurs K., Fagerlund T., Wolz W., Heffron J.J., Muller C.R., McCarthy T.V. Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia genotype-phenotype correlation . Am J Hum Genet. 62:1998;599-609.
8. Harrison G.G. orcine malignant hyperthermia. Int Anaesthesiol Clin. 17:1979;25-61.
9. Fujii J., Otsu K., Zorzato F., de Leon S., Khanna V.K., Weiler J.E., O'Brien P.J., MacLennan D.H. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science. 253:1991;448-451.
10. Otsu K., Khanna V.K., Archibald A.L., MacLennan D.H. Cosegregation of porcine malignant hyperthermia and a probable causal mutation in the skeletal muscle ryanodine receptor gene in backcross families. Genomics. 11:1991;744-750.
11. 2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia. J Biol Chem. 269:1994;9413-9415.
12. 2+ release channels . Am J Med. 104:1998;470-486.
13. Fletcher J.E., Mayerberger S., Tripolitis L., Yudkowsky M., Rosenberg H. Fatty acids markedly lower the threshold for halothane-induced calcium release from the terminal cisternae in human and porcine normal and malignant hyperthermia susceptible skeletal muscle. Life Sci. 49:1991;1651-1657.
14. Fletcher J.E., Tripolitis L., Erwin K., Hanson S., Rosenberg H., Conti P.A., Beech J. Fatty acids modulate calcium-induced calcium release from skeletal muscle heavy sarcoplasmic reticulum fractions implications for malignant hyperthermia . Biochem Cell Biol. 68:1993;1195-1201.
15. Weber A. The mechanism of action of caffeine on sarcoplasmic reticulum. J Gen Physiol. 52:1968;760-772.
16. Fairhurst A.S., Hasselbach W. Calcium efflux from a heavy sarcotubular fraction. Effects of ryanodine, caffeine and magnesium. Eur J Biochem. 13:1970;504-509.
17. 2+ release. J Biol Chem. 262:1987;6135-6141.
18. 2+-release channel function. Biochem J. 337:1999;345-361.
19. O'Driscoll S., McCarthy T.V., Eichinger H.M., Erhardt W., Lehmann-Horn F., Hermann-Frank A. Calmodulin sensitivity of the sarcoplasmic reticulum ryanodine receptor from normal and malignant-hyperthermia-susceptible muscle. Biochem J. 319:1996;421-426.
20. 2+ release channel. Circ Res. 67:1990;84-94.
21. 2+ release channel in skeletal muscle. J Membr Biol. 142:1994;281-288.
22. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
23. 2+ release from sarcoplasmic reticulum of normal and malignant hyperthermia susceptible pig muscles. Biochim Biophys Acta. 775:1984;320-327.
24. Gronert G.A., Heffron J.J., Taylor S.R. Skeletal muscle sarcoplasmic reticulum in porcine malignant hyperthermia. Eur J Pharmacol. 58:1979;179-187.
25. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem. 272:1997;26332-26339.
26. 2+ release channel function and severe central core disease. Proc Natl Acad Sci USA. 96:1999;4164-4169.
27. Ellis F.R., Heffron J.J. Clinical and biochemical aspects of malignant hyperpyrexia. Rec Adv Anaesth Analg. 15:1985;173-207.
28. Nelson T.E. Halothane effects on human malignant hyperthermia skeletal muscle single calcium-release channels in planar lipid bilayers. Anesthesiology. 76:1992;588-595.
29. Kawasaki T., Kasai M. Regulation of calcium channel in sarcoplasmic reticulum by calsequestrin. Biochem Biophys Res Commun. 199:1994;1120-1127.
30. 2+ release. J Biol Chem. 267:1992;20850-20856.
31. 2+] measured in vivo in patients susceptible to malignant hyperthermia. Anesthesiology. 76:1992;711-719.
32. 2+ in the ryanodine receptor of human malignant hyperthermia. Am J Physiol. 261:1991;C237-C245.